TOKYO, Mar 27 (Pulse News Wire) – Convano Inc. (6574.T) announced its subsidiary, Synksh Healthcare Co., Ltd., signed a contract with CM Plus to seek PMDA approval for botulinum toxin products in Japan.
The agreement covers foundational data organization, regulatory strategy evaluation, quality assessment, clinical studies, and application strategy recommendations. Synksh Healthcare aims to secure domestic manufacturing and sales approval for botulinum toxin products, which had global net revenues of approximately $1.7 billion and $1.4 billion for Botox Therapeutic and Botox Cosmetic respectively in 2024. The contract is expected to enhance strategic planning and expedite the approval process while minimizing costs within the fiscal year ending March 2026.
For the fiscal year ending March 2027, the impact on revenue and operating profit is anticipated to remain minor due to expenses being accounted for but without projected sales revenue included in initial forecasts. Revenue is forecasted at ¥23.70 billion and operating profit at ¥9.500 billion. However, successful approval could significantly boost future performance, particularly through expanded distribution channels and cross-selling opportunities.
Further developments will be disclosed as necessary.
🔴 Confidence: Review recommended AI-translated content.